MINI-REVIEW

Diabetes-associated infections: development of antimicrobial resistance and possible treatment strategies

Muhammad Sajid Hamid Akash1· Kanwal Rehman2 · Fareeha Fiayyaz1,3 · Shakila Sabir1,4 · Mohsin Khurshid3

Received: 15 September 2019 / Revised: 19 January 2020 / Accepted: 22 January 2020 / Published online: 3 February 2020
© Springer-Verlag GmbH Germany, part of Springer Nature 2020

Abstract
Diabetes mellitus is associated with various types of infections notably skin, mucous membrane, soft tissue, urinary tract, respiratory tract and surgical and/or hospital-associated infections. The reason behind this frequent association with infections is an immunocompromised state of diabetic patient because uncontrolled hyperglycemia impairs overall immunity of diabetic patient via involvement of various mechanistic pathways that lead to the diabetic patient as immunocompromised. There are specific microbes that are associated with each type of infection and their presence indicates specific type of infections. For instance, \textit{E. coli} and \textit{Klebsiella} are the most common causative pathogens responsible for the development of urinary tract infections. Diabetic-foot infections commonly occur in diabetic patients. In this article, we have mainly focused on the association of diabetes mellitus with various types of bacterial infections and the pattern of resistance against antimicrobial agents that are frequently used for the treatment of diabetes-associated infections. Moreover, we have also summarized the possible treatment strategies against diabetes-associated infections.

Keywords Diabetes-foot infections · Diabetes-associated surgical site infections · Antimicrobial resistance

Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder and one of the major causes of morbidity globally (Matusda and De Fronzo 1999). It is estimated that risk of DM will be greatly increased in the future. Between 1990 and 2010, the incidence of DM nearly tripled with 1.9 million new cases diagnosed in 2010 in USA (Yu et al. 2014). According to the World Health Organization, America, Bangladesh, India, Italy, Brazil, Russia, Pakistan, China, Japan and Indonesia, are the top ten countries with highest number of diabetic patients (Noor et al. 2015). T2DM is a heterogeneous group of disorders characterized by impaired insulin secretion, variable degrees of insulin resistance, and increased glucose production which is more common and mainly known disease of the elderly age. In adults, there is increased chance of early-onset of DM especially in industrialized countries. In 2011, the incidence of DM in people older than 65 years was 26.9% in USA and 11.3% in people older than 20 years (Apelqvist et al. 2000).

DM is a known risk factor for certain infectious diseases because diabetic individuals are in an immunocompromised due to their uncontrolled diabetes mellitus notably hyperglycemia (Shah and Hux 2003; Muller et al. 2005). Due to which there is a higher risk of number of other medical complications including eye problems and blindness, cardiovascular disease, lower extremity amputations and renal disease in diabetic individuals as compared to that in non-diabetic individuals. Among the various causative factors, hyperglycemia is one of the main culprits to impair the overall immunity of diabetic patient via involvement of various mechanistic pathways. Immunocompromised state is invariable in all diabetic patients. Not all diabetic patients are
immune-compromised except those patients having uncontrolled diabetes are considered immunocompromised due to negative effects of hyperglycemic environment that favors immune dysfunction such as damage to neutrophil function, impairment of antioxidant system and humoral immunity as shown in Fig. 1 (Casqueiro et al. 2012a; Calliari et al. 2019). High blood glucose impairs both innate and adaptive immunity through various mechanisms. Chronic hyperglycemia in diabetic patients can result in acidosis, which reduces the activity of immune system. Upon treatment of acidosis and hyperglycemia, the effects can be reversible (Casqueiro et al. 2012b). Immune-compromised is a heterogeneous group of diseases affecting various components of the immune system. The immune-compromised states can lead to different disorders that result in impairment of human immune system including human immunodeficiency virus infection, primary immune deficiency, and immunosuppression-related medical treatment, such as high-dose corticosteroid uses or transplantation therapy. Among these, human immunodeficiency virus infections are the most notorious. Clinical complications in immune-compromised patients vary from severe infections to unusual malignancies affecting major organs (Zheng and Zhang 2014).

In this article, we have summarized the findings of studies related to the association of DM with infectious diseases and risk of infection that is more common in diabetic patients. We have also focused that how antimicrobial resistance is developed during infection against antibiotics given to the diabetic patient. Furthermore, we have also provided the possible treatment strategies against DM-associated infections.

### Urinary tract infections in diabetic conditions

Diabetic patients are at increased risk of infectious diseases and most important and frequent site of infection is urinary tract (Patterson and Andriole 1997; Joshi et al. 1999; Shah and Hux 2003; Boyko et al. 2005). In general population, one of the most common bacterial infection is urinary tract infections with an overall estimated rate of incidence of 17.5/1000 person in a year (Laupland et al. 2007). In American study conducted on a health service data base with more than 70,000 patients with type 2 diabetes, it has been found that 8.2% were diagnosed with urinary tract infection during 1 year with incidence increasing with age (Yu et al. 2014). In another database study, it was also found that urinary tract infections were more common in diabetic patients as compared to that of non-diabetic patients among 89,790 matched pairs of patients with and without type 2 diabetes mellitus (Fu et al. 2014). Patients with DM are at increased risk of developing acute pyelonephritis, asymptomatic bacteriuria and other complications of urinary tract infections. For the development of symptomatic urinary tract infections and asymptomatic bacteriuria, the most common causative agents are *K. pneumoniae* and *E. coli* (Ribera et al. 2006). It has been warned that urinary tract infections would be positioned among the top ten concurrent or complicating illnesses during the lifetime course for the management of DM (Wheat 1980). It has been reported that up to 50% of women had at least one urinary tract infection during

![Diabetes-associated microbial infections](#)

**Fig. 1** Schematic representation of pathogenesis of diabetes-associated infections. Adapted from (Casqueiro et al. 2012a; Calliari et al. 2019)
their period of life (Barnett and Stephens 1997). More severe manifestations of urinary tract infections seemed to be associated with T2DM. A 12-month prospective cohort study proved that like T2DM, patients with T1DM are also at higher risk of urinary tract infections, lower respiratory tract infection as well as skin and soft tissues infections, indicating increased risks of common infections in both type 1 and type 2 diabetes (Muller et al. 2005). Similar to T2DM, T1DM is also mainly engaged with impairment in innate and adaptive immune system, ultimately leading towards increased risk of infections. Several evidences have suggested that hyperglycemia is the promoting factor for bacterial infections, also leading towards increased consumption of antibiotics. Additionally, these infections may lead to kidney injury either by direct invasion of pathogen or endotoxin, causing further complications (Simonsen et al. 2015). Asymptomatic bacteriuria to lower urinary tract infections, pyelonephritis, and severe urosepsis are the spectrum of urinary tract infections in patients suffering from DM. Emphysematous cystitis and pyelonephritis, renal abscesses and renal papillary necrosis are serious complications occurring in urinary tract infections. All these complications are frequently found in T2DM as compared to general population (Kofteridis et al. 2009; Mnif et al. 2013). In one study, the probability of hospital-acquired acute pyelonephritis was estimated to increase in case of DM by 20 to 30-fold in patients with less than 44 years of age, while, in patients over the age of 44 years, probability was 3–5-fold (Nicolle et al. 1996). Incidence of bilateral kidney infection also found to be increased in patients with DM (Hakeem et al. 2009). Additionally, there are more chances of bacteremia in diabetic patients owing urinary tract infections in comparison to non-diabetic individuals (Carton et al. 1992).

Several factors are associated with increased risk of urinary tract infections in diabetic patients includes, long term complications, metabolic control, age, primarily diabetic cystopathy and nephropathy (Brown et al. 2005). 22 observational studies (5 follow-up and 16 cross-sectional studies) published between 1966 and 2007 have reported that there is risk of asymptomatic bacteriuria in diabetic patients. Meta-analysis revealed that the chances of asymptomatic bacteriuria was found in 12.2% diabetic patients which was less likely to occur in 4.5% of patients that were taken from the healthy control group. In both women and men, prevalence of asymptomatic bacteriuria was higher either with DM or compared with healthy controls (Raz 2003). Recently, a study conducted on health service database with more than 70,000 patients with T2DM, has found that 8.2% were diagnosed with urinary tract infections during 1 year (Yu et al. 2014). In this study, it was also found that urinary tract infections were more common in men and women with DM than in those individuals without DM.

### Bacteriology of urinary tract infections in diabetic conditions

Bacteria that are more likely to involve in urinary tract infections are found to be similar in both the individuals with and without DM but also elicits complicated urinary tract infections (Nicolle 2001). In diabetic patients, identified bacteria, i.e., *Enterococcus* spp. (4%), *Staphylococcus* spp. (5%), *Klebsiella* spp. (6%), and *E. coli* (71%). *Enterococcus* spp. were more commonly found than *Klebsiella* spp. and *Staphylococcus* spp. in patients without DM. Rates of other species such as *Proteus* spp., *Pseudomonas* spp. and other bacteria such as *Streptococcus B* were found close in both groups of individuals (Table 1) (Malmartel and Ghasarossian 2016). As *E. coli* causes majority of infections in uncomplicated urinary tract infections. However, in these patients, other strains are also cultured frequently. For example, one study reported that 47% of urinary tract infections in diabetic patients and 68% chance of urinary tract infections in non-diabetic patients was due to more common uropathogen named as *E. coli* (Lye et al. 1992). Uropathogen other than *E. coli* also found in diabetic individuals, include *Enterococcus faecalis*, *Proteus* spp., *Klebsiella* spp., *Enterobacter* spp., and Group B *Streptococci* (Cook et al.

### Table 1  Bacteria responsible for urinary tract infection in patients with and without diabetes mellitus after matching. Adopted from (Malmartel and Ghasarossian 2016)

| Bacteria               | Patients with diabetes N=124 (%) | Patients without diabetes N=246 (%) | P value | Patients with uncontrolled diabetes N=100 (%) | Patients with controlled diabetes N=24 (%) | P value |
|------------------------|----------------------------------|------------------------------------|---------|-----------------------------------------------|------------------------------------------|---------|
| *Escherichia coli*     | 88 (71)                          | 169 (69)                           | 0.74    | 72 (72)                                       | 16 (67)                                  | 0.79    |
| *Enterococcus* spp.    | 5 (4)                            | 25 (10)                            | 0.07    | 5 (5)                                         | 0                                        | –       |
| *Klebsiella* spp.      | 8 (6)                            | 11 (4)                             | 0.57    | 5 (5)                                         | 3 (13)                                   | 0.17    |
| *Proteus* spp.         | 3 (2)                            | 10 (4)                             | 0.56    | 3 (3)                                         | 0                                        | –       |
| *Staphylococcus* spp.  | 6 (5)                            | 6 (2)                              | 0.23    | 4 (4)                                         | 2 (8)                                    | 0.3     |
| *Pseudomonas* spp.     | 1 (1)                            | 11 (4)                             | 0.07    | 1 (1)                                         | 0                                        | –       |
| Other bacteria         | 13 (10)                          | 14 (6)                             | 0.14    | 10 (10)                                       | 3 (13)                                   | 0.7     |
Antimicrobial resistance in urinary tract infections in diabetic conditions

It has been observed that isolated strains of *E. coli* show similar rates of resistance against nitrofurantoin, ciprofloxacin, ampicillin and co-trimoxazole in both diabetic and non-diabetic patients. An association has been found between the presence of co-trimoxazole resistance and DM due to recent hospitalization and use of the same drug (Wright et al. 1999) but no correlation has been reported between *E. coli* resistance against co-trimoxazole or quinolones and DM in out-patients (Steinke et al. 1999; Meiland et al. 2004).

Treatment strategies for urinary tract infections in diabetic conditions

Antimicrobial treatment

Regarding the outcomes of treatment strategies for asymptomatic bacteriuria in patients with DM, few clinical trials have been conducted (Forland et al. 1977; Forland and Thomas 1985). The results of these clinical trials indicate that (1) 2 weeks and 6 weeks of treatment have same effectiveness; (2) the rate of recurrence of urinary tract infection was high, even after following antibiotic treatment for longer duration; (3) mostly re-infections were recurrent (4/8 weeks post-therapy) and these reversions were not with same microorganism. Among bacteriuric women with DM, physician should have awareness about high prevalence of underlying structural genitourinary abnormalities (Forland and Thomas 1985). If asymptomatic bacteriuria leads to serious complications as functional deterioration of kidney then there is need for screening of asymptomatic bacteriuria in diabetic female (Nicolle 2000). Since due to unavailability of such evidences (Schmaldienst et al. 2002) but not including all (Zhanel et al. 1990a; Patterson and Andriole 1997) believe that there is no justified treatment for asymptomatic bacteriuria. A randomized controlled trial has been conducted in which 108 diabetic women with asymptomatic bacteriuria diagnosed by two urine cultures showing ≥ 105 colony forming units of an organism per milliliter were randomized to receive a 3 or 14-day course of either co-trimoxazole or placebo (Harding et al. 2002). Patients in group of antibiotic treatment who were infected with resistant microorganism was provided with ciprofloxacin but this study was discontinued due to the occurrence of early relapses in first six patients that were prescribed to an antibiotic regimen of 3-day. Screening of all patients were done after every three months for the detection of bacteriuria. Further suppressive antimicrobial therapy was provided to women confirmed as bacteriuric that were assigned to group of antibiotic therapy. When compared with 20% of women who received antibiotics, only 78% of placebo recipients showed bacteriuria following 4 weeks at the end of initial course of therapy. 23 out of 55 women (42%) in antimicrobial-therapy group and 20 out of 50 women (40%) in the placebo group had at least one episode of symptomatic urinary tract infections during mean follow-up of 27 months. In placebo and antimicrobial-therapy group, the time to first symptomatic episode was similar as were the rates of hospitalization for urinary tract infections and any symptomatic urinary tract infections which exhibited that treatment of asymptomatic bacteriuria in diabetic women fails to decrease the risk of complications. For the screening and/or treatment of asymptomatic bacteriuria, DM itself should not be considered as an indication (Harding et al. 2002). Infectious Diseases Society of America recommends a 3-day course with co-trimoxazole as standard therapy for uncomplicated acute phase of bacterial cystitis. Alternative treatment can be used in which diabetic patient can be prescribed fluoroquinolone or trimethoprim alone. Other fluoroquinolones also show similar rate of effectiveness but these should only be used as alternative treatment in communities with higher resistance to co-trimoxazole (Warren et al. 1999). For the treatment of complicated lower urinary tract infections, the efficacy of 5-day ofloxacin treatment was compared with 10-day regimen that was performed by double-blind study (Hoepelman et al. 2003). 416 women were included in this study with no confirmed information that how many of them have DM. The authors concluded that both treatments have similar effectiveness (Hoepelman et al. 2003). Another randomized double-blind study which recruited 85 (20%) women with DM, concluded that 7-day treatment with ciprofloxacin or with ofloxacin resulted in cure rate of 90% and 87%, respectively (Raz et al. 2000). Cefixime, a third-generation cephalosporin is well absorbed when taken orally and has plasma half-life of 3–4 h, elicits better efficiency against urinary tract infections (Chaudhary et al. 2015). But unfortunately, resistance against cefixime is increased in diabetic patients, suggesting amendments in treatment strategies for urinary tract infections in diabetic patients (Malmartel and Ghasarossian 2016).

Preventive measures

The need for additional non-antimicrobial strategies is due to increasing problem of resistant uropathogens (Gupta et al. 1999). General advice comprises sufficient intake of fluid, minimum spermicides use, during voiding make sure that the bladder is completely emptied and restrictive use of catheter. Ingestion of cranberry juice is an interesting...
possible preventive measure. At first, it was thought that cranberry juice had beneficial role in the acidification of urine. Recently, it has been recognized that cranberry juice inhibit the adherence of bacteria to the uroepithelial cells and considered as one of most important preventive measure (Raz et al. 2004). Oral or vaginal administration of Lactobacillus is another possible preventive strategy to control urinary tract infections in diabetic conditions. They are thought to protect against urinary tract infections by competitive exclusion of uropathogens and are the part of commensal vaginal flora (Boris et al. 1998). The recurrence of urinary tract infections in women with E. coli infection is reduced by a regular drinking of cranberry juice but not of Lactobacillus GG drink (Kontiokari et al. 2001). The recurrence rate of urinary tract infections in postmenopausal women is reduced by the estrogen administration especially if administered vaginally (Hextall 2000). An essential step in the pathogenesis of urinary tract infections is adherence of E. coli to uroepithelial cell. Preventive measures would lead to decreased incidence of urinary tract infections. Recently, attention has been diverged towards the vaccine development. This vaccine is based on type 1 fimbriae of E. coli. It has been observed that this vaccine is helpful in decreasing the incidence of urinary tract infections through the inhibition of E. coli attachment to uroepithelial cells in monkeys to whom vaccine were provided (Langermann et al. 1997, 2000). It is also demonstrated that decrease in the adherence of type-1 fimbriated E. coli to diabetic uroepithelial cells by addition of vaccine-induced antiserum to uroepithelial cells was occurred that was isolated from diabetic women (Meiland et al. 2001). Although, this vaccine is safe but it proved to be only 30% effective in young sexually active women, so further clinical studies have been stopped. Bacterial vaginosis, mainly responsible for vaginal discharge in women of reproductive age, also engaged with high recurrence rate. Probiotics are helpful for preventing recurrences of bacterial vaginosis (Parma et al. 2014). Generally, normal vaginal microbiota is dominated by lactobacilli, and strong evidence has suggested negative association between bacterial vaginosis and presence of lactobacilli. Although, some conflicting studies are still present. Yet, most studies have suggested positive outcomes upon supplementation with probiotics (Falagas et al. 2007).

**Skin and soft tissue infections in diabetic conditions**

In diabetic individuals, skin and soft tissue infections are leading causes of morbidity and occasionally mortality (DiNubile and Lipsky 2004; Kao et al. 2005; Homer-Vannia-sinkam 2007; Sendi et al. 2008). At all anatomic sites, these infections can occur but the most common site is foot and it is frequently affected in diabetic patients (Frykberg et al. 2006). Annually, about 111,000 diabetic persons suffering from foot infections are hospitalized in America. It contributes to nearly 60% of total lower extremity amputations (Lipsky 2004). Both in ambulatory and hospitalized patients, S. aureus is most common pathogen that is present in skin and soft tissues infections (Kirby et al. 2002; Liu et al. 2008; Odell 2010). It is estimated that lifetime risk of developing a foot ulcer is up to 25% in patients with DM (Singh et al. 2005). Approximately 3% incidences of diabetic-foot ulcers are reported annually while, in America and United Kingdom, the reported incidences of diabetic-foot ulcers are as high as 10% (Reiber et al. 1999). Once after the development of foot ulcer, risk of wound progression increases that may finally lead towards amputation. The risk of diabetic ulceration is up to 85% of the cases that leads to amputation (Reiber et al. 1999).

For the development of diabetic-foot infections, there are several factors that influence the diabetic patients. These factors include immunopathy, neuropathy and vasculopathy. Peripheral neuropathy is considered the most prominent risk factor that occur early in the pathogenesis of diabetic foot infections and also diabetic foot ulcers (Clayton and Elasy 2009). Neuropathy results in diabetic foot ulcers that is more than 60% (Dyck et al. 1999; Bowering 2001). In diabetic patients, neuropathy is established in sensory, motor and autonomic parts of the nervous system (Bowering 2001). An imbalance between flexion and extension of the affected foot occur as a result of impairment in the innervations of intrinsic muscles of the foot. Abnormal bony prominences and pressure points is due to the abnormalities of anatomic foot that will gradually lead towards ulceration and skin breakdown. A reduction in functionality of sweat and oil gland is due to autonomic neuropathy. So, natural ability of foot to moisturize the overlying skin is lost and skin becomes dry. It also becomes more susceptible to tears and it will subsequently lead towards the development of infection. The loss of sensation impairs the development of ulcerations. Patients are often unable to detect their lower extremities as trauma occurs at the affected site. Many wounds go unnoticed because of this and gradually become worst.

**Microbiology of skin and soft tissue infections in diabetic conditions**

The skin and mucous membranes of diabetic patients have certain common bacterial and fungal pathogens, such as Candida albicans and S. aureus. Pathogenic bacteria that may predispose susceptible patient to lower extremity infection is found to colonize in diabetic foot ulcerations. According to a study of 84 randomly selected hospitalized patients with severe diabetic foot infections, 83% of cultures demonstrated that existence of polymicrobial flora with an
average of 2.8 species per specimen and ratio of aerobic to anaerobic bacteria is 3:1 (Hobizal and Wukich 2012). *Staphylococcus epidermidis, S. aureus*, and *Streptococcus* species were the most frequently isolated organisms. *Peptostreptococcus magnus* and *Bacteroides fragilis* were observed among anaerobes (Calhoun et al. 2002). In various studies, it is found that the most common organisms were aerobic gram-positive cocci isolated from the wounds of diabetic patients, especially diabetic foot infections. *Staphylococcus aureus, Enterococcus*, facultative gram-negative bacilli, and group B streptococci are most commonly identified pathogens in the cultures of limb-threatening infections.

**Treatment strategies for skin and soft tissue infections in diabetic conditions**

**Preventive measures**

For the treatment of diabetic foot infections, there is a formulated guidelines and key recommendations provided by infectious diseases society of America. According to these guidelines, it is stated that an empirical treatment of antimicrobial agents should be applied on the basis of likely pathologic agents and infection severity (Lipsky et al. 2006). Antimicrobial agent is more active against gram-positive cocci with special attention for methicillin-resistant *Staphylococcus aureus* which are included in the antibiotic treatment. Extended coverage for gram-negative bacilli and enterococcus species included in the previously treated or severe diabetic foot infections. Anti-anaerobic therapy is required for foul smelling and gangrenous wounds. In the selection of treatment program as well as concerned side effects of potential drug, bioavailability, pharmacokinetics, route of administration and frequency are all important factors and have their role in the cost of therapy (McKinnon et al. 1997). It has been reported that patients treated with ertapenem have clinical and microbiological outcomes that were equivalent to those treated with piperacillin/tazobactam (Singh et al. 2005). This study recommends that dose of ertapenem that is given once a daily is beneficial in setting of diabetic foot infections, although the fact about the ertapenem is unable to provide protection from most of *P. aeruginosa* or enterococci. It also indicates that in polymicrobial diabetic foot infections, these organisms may only be contaminants. Based upon clinical studies, the duration of antibiotic therapy that is considered an optimal duration has yet to be properly defined. In general, treatment of mild and severe diabetic foot infections started from 2–4 weeks of antibiotic therapy and route of administration is intravenous and another is started from 4–6 weeks of antibiotic therapy. Another way for the control of moderate to severe diabetic foot infection, is the surgical management and it includes drainage, debridement of non-viable soft tissue and bone and aggressive incision. Modern approach is to use adjunctive therapies which include application of negative pressure wound therapy, hyperbaric oxygen treatment and use of antibiotic impregnated beads (Armstrong and Lavery 2005; Krause et al. 2009; Chen et al. 2010). The role of antibiotics remains unclear for the treatment of foot ulcers in patients with DM (Lipsky et al. 2004). However, a high priority for the management of infected diabetic foot as part of multidisciplinary care (Reiber and Raugi 2005) is revascularization (van Baal 2004). The roles of adjunctive therapies are yet to be established (Cavanagh et al. 2005).

**Treatment strategies**

It is recommended that regular foot inspection and adequate footwear are important measures that should be taken by diabetic patients to control diabetic foot infections (Robson et al. 1998; Boulton et al. 1999; Foot 2007). However, the majority of diabetic patients do not care their feet and or regular inspections of their feet (Uccioli et al. 1995; Robson et al. 1998; Boulton et al. 1999). These studies indicate that strategies including regular inspection and examination of feet and footwear, identification of high risk patient, education of patient, family and health care staff, use of appropriate footwear, and treatment of nonulcerative pathology can increase the awareness of the problem and aptitude for self-management and ability to decrease the incidence of minor foot lesions. Several studies have reported that combination of chiropodist care and other strategies reduce the prevalence of non-ulcer pathology (Litzelman et al. 1993, 1997; Rönnermaa et al. 1997). Proper treatment of callousities, cracked skin, dry skin and nail deformities is essential and specific skills are required (Boulton et al. 1999). A study conducted in Sweden has found that only a few chiropodists had a close cooperation with the health care system, and only 14–22% had any kind of education with regard to diabetic foot (Apelqvist et al. 2000). In a cross-sectional population-based study, 80% of diabetic individuals older than 25 years claimed to have access to chiropodist (Gottrup 2004). A number of studies have shown that such footwear, when available and used, can prevent re-ulceration in patients with previous foot ulcers (Edmonds et al. 1986; Chantelau et al. 1990; Breuer 1994; Chantelau and Haage 1994; Mueller 1997).

**Respiratory tract infections in diabetic conditions**

Increased hospitalizations in diabetic individuals as compared to those without diabetes are the most important cause of respiratory tract infections. Bacterial, fungal and viral are the most common etiological factors in diabetic patients.
Table 2 Pooled estimates of association of diabetes mellitus with surgical site infections. Adopted from (Martin et al. 2016)

| Surgery type               | No. of studies | Pooled estimate | 95% prediction interval | I² or % |
|----------------------------|----------------|----------------|-------------------------|---------|
| Gynecological              | 6              | 1.61           | 1.15–2.24               | 4.0     |
| Colorectal                 | 7              | 1.16           | 0.93–1.44               | 9.5     |
| Arthroplasty               | 6              | 1.26           | 1.01–1.66               | 11.7    |
| Breast                     | 5              | 1.58           | 0.91–2.72               | 2.7     |
| Cardiac                    | 15             | 2.03           | 1.13–4.05               | 22.4    |
| Spinal                     | 14             | 1.66           | 1.10–2.32               | 8.1     |
| Other/Multiple surgery     | 37             | 1.46           | 1.07–2.00               | 41.5    |

Bacteriology of respiratory tract infections in diabetic conditions

The type of organisms that are responsible for community-acquired pneumonia in diabetic patients vary from that of non-diabetic individuals, with an increased prevalence of Gram-negative bacteria such as K. pneumoniae and S. aureus [81]. Most important causative organism that are responsible for the occurrence of respiratory tract infections-associated with DM are S. pneumoniae and influenza virus (Arancibia et al. 2014). It has been expected that in diabetic patients, the cases of fungal infections that are caused by Mucorales are 50–75% while predisposing factor is acidosis. For onychomycosis in diabetic patients, the second responsible microorganism is Aspergillus (Jones 2010). It has been found that during the first four days of hospitalization, the most common bacteria causing hospital-acquired pneumonia are S. pneumoniae, Enterobacter, K. pneumoniae, Serratia, E. coli, S. aureus (methicillin-susceptible), Proteus and Haemophilus influenzae (Zhang et al. 2014; Klekotka et al. 2015). The predominance of bacteria from the 5th day of hospitalization include Acinetobacter spp., Staphylococcus aureus (methicillin-resistant MRSA), E. coli, L. pneumophila, Pseudomonas aeruginosa, and K. pneumoniae (Klekotka et al. 2015). In European countries and America, S. aureus is most commonly isolated bacteria associated with hospital-acquired pneumonia (Jones 2010b).

Antimicrobial resistance in respiratory tract infections in diabetic conditions

Klebsiella pneumoniae showed resistance to fosfomycin (26.7% vs 37.6%) and sulfamethoxazole (22.7% vs 32.5%) in pneumonia among diabetic patients. In intensive care unit, resistance rates of K. pneumoniae have been reported to be significantly lower in diabetic patients than that in non-diabetic individuals against fosfomycin (42.6% vs 62.6%) aztreonam (53.4% vs 69.5%), tobramycin (42.5% vs 61.0%), meropenem (37.7% vs 59.8%), amikacin (37.8% vs 52.8%) and cefotetan (45.2% vs 63.2%). Only sulfamethoxazole...
### Table 3  Treatment strategies of common microbial infections in diabetic conditions. Adapted from (Peleg et al. 2007)

| Type of infections          | Organisms                                                                 | Empirical antimicrobial treatment<sup>a</sup> | Alternative | Other treatment                                                                 |
|----------------------------|---------------------------------------------------------------------------|-----------------------------------------------|-------------|---------------------------------------------------------------------------------|
| Skin and soft tissueb      |                                                                           |                                               |             |                                                                                 |
| Cellulitis                 | *S. aureus, S. pyogenes*, less common gram-negative aerobes and anaerobes  | Nafcillin/flu(dicloxacillin)/2 g/IV 4–6 h      | Cephazolin 1 g IV 8 h or clindamycin 600 mg IV 8 h or 300–450 mg PO 8 h or vancomycin 1 g IV 12 h | N/A                                                                                 |
| Diabetic foot infection    | *S. aureus, S. pyogenes*, gram-negative aerobes including *Pseudomonas aeruginosa*, anaerobes, often polymicrobial | Mild–moderate<br>Usually an oral regimen to cover gram + ve and common gram-negative organisms, e.g., Amoxicillin-clavulanate 875/125 mg PO 12 h or ampicillin/subactam 3 g IV 6 h<br>Severe<br>Ticarcillin-clavulanate 3.0–0.1 g IV 6 h or Piperacillin-tazobactam 3.375 g IV 8 h or Mero/imipenem-cilastatin 500 mg–g 8/6 h | Cephalexin 500 mg PO 6 h plus metronidazole 400 mg PO 8–12 h, broad-spectrum fluoroquinolone, or ciprofloxacin 500 mg PO 12 h plus Clindamycin 600 mg IV 8 h or 300–450 mg PO 8 h | Surgical review, assess requirement for revascularization, wound debridement, avoidance of pressure-induced ischaemia with orthotic devices N/A |
| Necrotizing fasciitis      | *S. pyogenes* or *Clostridium spp.* or polymicrobial                        | Meropenem 1 g IV 8 h plus clindamycin 600 mg IV 8 h or lincomycin 600 mg IV 8 h | Ampicillin-sulbactam 1.5–3 g 6–8 h or piperacillin-tazobactam 3.375 g 6–8 h, plus ciprofloxacin400 mg IV 12 h plus clindamycin 600–900 mg IV 8 h | Surgical removal of devitalized tissue is the basis of treatment |
| Community acquired pneumonia| *S. pneumoniae, M. pneumoniae, C. pneumoniae, Legionella spp., H. influenzae, S. aureus, K. pneumoniae, M. tuberculosis* | Mild<br>An advanced macrolide<sup>d</sup> or amoxy-cillin 1 g PO 8 h plus doxycycline 200 mg PO for first dose and then 100 mg PO daily<br>Moderate<br>An advanced macrolide<sup>d</sup> Plus, a β-lactam (benzyl penicillin 1.2 g IV 6 h or ampicillin 1 g IV 6 h or cefotaxime/ceftriaxone 1 g IV daily or ampicillin-subactam)<br>Severe<sup>e</sup><br>Ceftriaxone 1 g IV daily or cefotaxime 1 g IV 8 h plus either an advanced macrolide<sup>d</sup> or a respiratory fluoroquinolone<sup>d</sup> | A respiratory fluoroquinoloned<br>A respiratory fluoroquinoloned<br>An antipseudomonal β-lactam plus, either an advanced macrolide<sup>d</sup> or a respiratory fluoroquinolone<sup>d</sup> | N/A<br>N/A<br>Requirement for antipseudomonal cover will depend on risk factors Local prevalence rates of community-acquired MRSA should guide empirical treatment and may include vancomycin 1 g IV 12 h or linezolid 600 mg IV 12 h |
| Urinary tract infections   | Asymptomatic bacteriuria                                                   | No treatment                                  | N/A         | N/A                                                                              |
|                            | Various, most frequently *Enterobacteriaceae*                             |                                               |             |                                                                                 |
### Table 3 (continued)

| Type of infections              | Organisms                                      | Empirical antimicrobial treatment$^a$ | Other treatment                                                                 |
|---------------------------------|------------------------------------------------|--------------------------------------|---------------------------------------------------------------------------------|
|                                 |                                                | First line                           | Alternative                                                                      |
| Cystitis                        | *Enterobacteriaceae, Staphylococcus saprophyticus, Enterococcus spp., rarely Candida spp.* | 3 days oral antibiotic treatment guided by local antibiotic sensitivity pattern e.g. trimethoprim-sulfamethoxazole orally daily | Trimethoprim 300 mg or norfloxacin 400 mg orally 12 h or ciprofloxacin 500 mg orally 12 h | N/A |
| Pyelonephritis                  |                                                | 14 days$^b$ oral/IV antibiotic treatment guided by local antibiotic sensitivity pattern. Ciprofloxacin 500/400 mg PO/IV 12 h or ampicillin 2 g IV 6 h plus gentamicin (see local dosing and monitoring guidelines) or ampicillin/sulbactam 1.5 g IV 6 h | Ceftriaxone 1 g IV daily or ceftaxime 1 g IV 8 h or ticarcillin-clavulanate 3.0–0.1 g IV 6 h or piperacillin-tazobactam 4.0–0.5 g IV 8 h | Emphysematous pyelonephritis is a rare but serious complication requiring early surgical intervention. Post-treatment urine microscopy and culture recommended in all |
| Other soft tissue infections    |                                                |                                      |                                                                                  |
| Necrotizing otitis externa      | *P. aeruginosa*                                | Ciprofloxacin 400 mg IV 12 h or ticarcillin-clavulanate 3.0–0.1 g IV 6 h or ceftazidime 2 g IV 12 h or ceftazidime 2 g IV 8 h plus gentamicin 4–6 mg/kg IV daily | Imipenem-cilastatin/meropenem 1 g IV 6/8 h | Otolaryngology review |
| Rhinocerebral mucormycosis      | *Rhizopus (>90%), mucor and absidia species*  | Amphotericin B 0.8–1.5 mg/kg IV daily | Lipid-based amphotericin B for those with renal impairment or posaconazole 800 mg PO daily in 2–4 divided doses | Control diabetic ketoacidosis if present. Surgical debridement required |

$^a$All treatment regimens are for average sized, non-pregnant patients with normal renal and liver function

$^b$If community-acquired MRSA is documented in the geographic area then empirical treatment for life-threatening infections should include vancomycin 1 g IV 12 h. An alternative treatment may be linezolid 600 mg IV 12 h or linezolid 600 mg IV 12 h. Treatment of other infections should be based on sensitivity data and may include clindamycin 300–450 mg orally 8 h or trimethoprim/sulfamethoxazole 160/800 mg orally 12 h.

$^c$Azithromycin or clarithromycin.

$^d$Moxifloxacin, levofloxacin, gemifloxacin.
exhibited a low resistance (13.8% vs 25.6%) in non-intensive care unit. Those with a higher HbA1c level showed significantly lower resistance to sulperazone (11.7% vs 40.0%) and fosfomycin (14.3% vs 66.7%) when compared with diabetic individuals having HbA1c < 6.5%.

**Treatment strategies for respiratory tract infections in diabetic conditions**

There are no known effective treatment strategies for respiratory tract infections in diabetic conditions. It has been reported that diabetic subjects having respiratory tract infections, respond appropriately to anti-tuberculous treatment (Kameda et al. 1990).

**Surgical site infections in diabetic conditions**

In United States, prevalence of DM is increasing day-by-day (Cheng et al. 2013) and nowadays, it has become an important that there should be an appropriate control and management of patients with DM to make possible prevention from infections-associated with hospital. It has been found that DM influence the surgical site infections and influence of hyperglycemia on surgical site infections has also been confirmed (Zimlichman et al. 2013). A total of 90 studies provided the estimates for the association between DM and surgical site infections have been summarized in Table 2 (Martin et al. 2016). Among the patients undergoing cardiac surgery, the actual pooled estimate was found highest. Mostly, diabetic patients do not survive long due to increase development of antimicrobial resistance against infections. This has been found that increased risk of surgical site infections was consistent across surgery types among diabetic patients except the gynecological and obstetrical surgery (Mu et al. 2011). It has been reported that glucose levels remain consistently higher in diabetic patients with surgical site infections receiving colorectal resection when compared with uninfected diabetic patients (Sehgal et al. 2011). Increased rates of infection in colorectal and bariatric surgery,(Kwon et al. 2013) orthopaedic spine surgery (Caputo et al. 2013) and cardiac surgery (Zerr et al. 1997; Furnary et al. 1999; Wilson and Sexton 2003) has been found to be associated with raised blood glucose level (Hardy et al. 2010; Jeon et al. 2012).

**Treatment strategies**

There are no known possible and effective treatment strategies for surgical site infection associated with DM. In Table 3, we have summarized the infections associated with DM and their possible treatment strategies (Peleg et al. 2007). The rates of morbidity and mortality increase due to these infections.

**Conclusion**

The aforementioned convincingly evidences strongly suggest the utmost need of appropriate hygiene conditions for diabetic patients in hospitals. Subsequently, such a palliative strategy can prophylactically secure future complication of antimicrobial resistance in diabetic patients. As it is better to spend one once on prevention then two once on treatment because the normal treatment regimen is ineffective against diabetic patients suffering from microbial infections in contrast to non-diabetics. Thus, radical amendments in hospital diabetic wards such as by providing them isolated and hygienic conditions can ultimately, subsides the consequences of antimicrobial resistance in diabetic patients. Additionally, further well-designed and randomized studies are required for accessing the significance of hygienic conditions and possibly expected favorable outcomes. Surely, such types of studies will also helpful for better understanding of radiological, laboratory as well as clinical characteristics of infections affiliated with diabetic patients. Furthermore, this study also urges policy makers to formulate an antimicrobial policy for diabetics for rational use of antibiotics.

**Acknowledgements**

This work was financially supported by the research Grants (5661/Punjab/NRPU/R&D/HEC/2016, 6429/Punjab/NRPU/R&D/HEC/2016 and 8365/Punjab/NRPU/R&D/HEC/2017) received from Higher Education Commission (HEC) of Pakistan.

**Compliance with ethical standards**

**Conflict of interest**

Authors declare that they do not have conflict of interest for this article.

**References**

Apelqvist J, Bakker K, Van Houtum WH, Nabuurs-Franssen MH, Schaper NC (2000) International consensus and practical guidelines on the management and the prevention of the diabetic foot. Diabetes Metab Res Rev 16:848–S92

Arancibia F et al (2014) Importance of *Legionella pneumophila* in the etiology of severe community-acquired pneumonia in Santiago, Chile. Chest 145:290–296

Armstrong DG, Lavery LA (2005) Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial. Lancet 366:1704–1710

Barker WH, Mulloloy JP (1982) Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 142:85–89

Barnett BJ, Stephens DS (1997) Urinary tract infection: an overview. Am J Med Sci 314:245–249
Jones RN (2010) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51:S81–S87

Joshi N, Caputo GM, Weitekamp MR, Karchmer A (1999) Infections in patients with diabetes mellitus. N Engl J Med 341:1906–1912

Kalim M et al (2000) Prospective study of prognostic factors in community-acquired bacteremic pneumococcal disease in five countries. J Infect Dis 182:840–847

Kameda K, Kawabata S, Masuda N (1990) Follow-up study of short course chemotherapy for pulmonary tuberculosis complicated with diabetes mellitus. Kekkaku 65:791–803

Kao LS, Knight MT, Lally KP, Mercer DW (2005) The impact of diabetes in patients with necrotizing soft tissue infections. Surg Infect 6:427–438

Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfeller MA, Group SP (2002) Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft tissue infections: report from the SENTRY antimicrobial surveillance program (2000). Diagn Microbiol Infect Dis 43:303–309

Klekotka RB, Mizgala E, Król W (2015) The etiology of lower respiratory tract infections in people with diabetes. Pneumonol Alergol Pol 83:401–408

Kofteridis DP et al (2009) Effect of diabetes mellitus on the clinical and microbiological features of hospitalized elderly patients with acute pyelonephritis. J Am Geriatr Soc 57:2125–2128

Kontiokari T, Sundqvist G, Meakin C, Kalla TP, Younger AS (2009) Outcome of transmetatarsal amputations in diabetics using antibiotic beads. Foot Ankle Int 30:486–493

Kwon S, Thompson R, Yanez D, Farrohki E, Flum D (2013) Importance of perioperative glycemic control in general surgery: a report from the surgical care and outcomes assessment program. Ann Surg 257:8–14

Langermann S et al (2000) Vaccination with fimh adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 182:1774–778

Kornum JB, Thomsen RW, Riis A, Lervang H-H, Schønheyder HC, Sorensen HT (2007) Type 2 diabetes and pneumonia outcomes: a population-based cohort study. Diabetes Care 30:2251–2257

Krause FG, deVries G, Meakin C, Kalla TP, Younger AS (2009) Outcome of transmetatarsal amputations in diabetics using antibiotic beads. Foot Ankle Int 30:486–493

Lipsky BA (2004a) Medical treatment of diabetic foot infections. Clin Infect Dis 39:S104–114

Lipsky BA et al (2004b) Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885–910

Lipsky B et al (2006) Infectious diseases society of America: diagnosis and treatment of diabetic foot infections. Plast Reconstr Surg 117:2125S–238S

Litzelman DK et al (1993) Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus: a randomized, controlled trial. Ann Intern Med 119:36–41

Litzelman DK, Marriot DJ, Vinicor F (1997) The role of footwear in the prevention of foot lesions in patients with NIDDM: conventional wisdom or evidence-based practice? Diabetes Care 20:156–162

Liu C et al (2008) A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004–2005. Clin Infect Dis 46:1637–1646

Lye W, Chan R, Lee E, Kumarasingshe G (1992) Urinary tract infections in patients with diabetes mellitus. J Infect 24:169–174

Malmartel A, Ghasarossian C (2016) Bacterial resistance in urinary tract infections in patients with diabetes matched with patients without diabetes. J Diabetes Complicat 30:705–709. https://doi.org/10.1016/j.jdiacomp.2016.01.005

Martin ET et al (2016) Diabetes and risk of surgical site infection: a systematic review and meta-analysis. Infect Control Hosp Epidemiol 37:88–99

Matusda M, De Fronzo R (1999) Insulin sensitivity indices obtained from oral glucose tolerance testing. Diabetes Care 22:1462–1470

McKinnon PS, Paladino JA, Grayson ML, Gibbons GW, Karchmer AW (1997) Cost-effectiveness of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 24:57–63

Meiland R, Geerlings S, Brouwer E (2001) Adherence of Escherichia coli to uroepithelial cells of women with diabetes mellitus (DM) can be inhibited by vaccine-induced anti-FimCH antisera [abstract no. L1349]. In: Proceedings of the 41th Interscience Congress on Antimicrobial Agents and Chemotherapy, pp 16–19

Meiland R, Geerlings S, De Neeling A, Hoepelman A (2004) Diabetes mellitus in itself is not a risk factor for antibiotic resistance in Escherichia coli isolated from patients with bacteriuria. Diabet Med 21:1032–1034

Mnif MF et al (2013) Complicated urinary tract infections associated with diabetes mellitus: pathogenesis, diagnosis and management. Indian J Endocrinol Metab 17:442–445

Mu Y, Edwards JR, Horan TC, Berrios-Torres SI, Fridkin SK (2011) Improving risk-adjusted measures of surgical site infection for the National Healthcare Safely Network. Infect Control Hosp Epidemiol 32:970–986

Mueller MJ (1997) Therapeutic footwear helps protect the diabetic foot. J Am Podiatr Med Assoc 87:360–364

Muller L et al (2005) Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41:281–288

Nicolle LE (2000) Asymptomatic bacteriuria in diabetic women. Diabetes Care 23:722–723

Nicole LE (2001) A practical guide to antimicrobial management of complicated urinary tract infection. Drugs Aging 18:243–254

Nicolle L, Friesen D, Harding G, Roos L (1996) Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992: impact of diabetes, pregnancy, and aboriginal origin. Clin Infect Dis 22:1051–1056

Noor S, Zubair M, Ahmad J (2015) Diabetic foot ulcer—a review on pathophysiology, classification and microbial etiology. Diabetes Metab Syndr 9:192–199

Odell CA (2010) Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) skin infections. Curr Opin Pediatr 22:273–277

Parma M, Stella Vanni V, Bertini M, Candiani M (2014) Probiotics in the prevention of recurrences of bacterial vaginosis. Altern Ther Health Med 20(Suppl 1):52–57

Patterson JE, Andriole VT (1997) Bacterial urinary tract infections in diabetes. Infect Dis Clin N Am 11:735–750

Peleg AY, Weeraratna T, McCarthy JS, Davis TME (2007) Common pathogens in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev 23:3–13

Raz R (2003) Asymptomatic bacteriuria. Clinical significance and management. Int J Antimicrob Agents 22:45–47

Raz R et al (2000) Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women. Eur J Clin Microbiol Infect Dis 19:327–331

Raz R, Chazan B, Dan M (2004) Cranberry juice and urinary tract infection. Clin Infect Dis 38:1413–1419

Springer
Reiber GE, Raugi GJ (2005) Preventing foot ulcers and amputations in diabetes. Lancet 366:1676–1677
Reiber GE et al (1999) Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings. Diabetes Care 22:157–162
Restrepo BI, Schlesinger LS (2013) Host-pathogen interactions in tuberculosis patients with type 2 diabetes mellitus. Tuberculosis 93:S10–14
Ribera M, Pascual R, Orozco D, Barba CP, Pedrera V, Gil V (2006) Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria. Eur J Clin Microbiol Infect Dis 25:389–393
Robson MC, Mustoe TA, Hunt TK (1998) The future of recombinant growth factors in wound healing. Am J Surg 176:805–828
Rönnemaa T, Hämäläinen H, Toikka T, Liukkonen I (1997) Evaluation of the impact of podiatrist care in the primary prevention of foot problems in diabetic subjects. Diabetes Care 20:1833–1837
Schmaldienst S, Dittrich E, Hörl WH (2002) Urinary tract infections after renal transplantation. Curr Opin Urol 12:125–130
Sehgal R et al (2011) Risk factors for surgical site infections after colorectal resection in diabetic patients. J Am Coll Surg 212:29–34
Sendi P, Johannson L, Norrby-Teglund A (2008) Invasive group B streptococcal disease in non-pregnant adults. Infection 36:100–111
Shah BR, Hux JE (2003) Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 26:510–513
Simonsen JR et al (2015) Bacterial infections in patients with type 1 diabetes: a 14-year follow-up study. BMJ Open Diabetes Res Care 3:e000067. https://doi.org/10.1136/bmjdrc-2014-000067
Singh N, Armstrong DG, Lipsky BA (2005) Preventing foot ulcers in patients with diabetes. JAMA 293:217–228
Steinke D, Seaton R, Phillips G, MacDonald T, Davey P (1999) Factors associated with trimethoprim-resistant bacteria isolated from urine samples. J Antimicrob Chemother 43:841–843
Thomsen RW, Hundborg HH, Lervang H-H, Johnsen SP, Sorensen HT, Schonheyder HC (2004) Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 27:70–76
Uccioli L et al (1995) Manufactured shoes in the prevention of diabetic foot ulcers. Diabetes Care 18:1376–1378
van Baal JG (2004) Surgical treatment of the infected diabetic foot. Clin Infect Dis 39:S123–128
Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE (1999) Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis 29:745–759
Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A (1997) Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 63:356–361
Zhanel GG, Harding GKM, Guay DRP (1990a) Asymptomatic bacteriuria: which patients should be treated? Arch Intern Med 150:1389–1396
Zhanel GG, Harding GKM, Nicolle LE (1990b) Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis 13:150–154
Zhanel GG, Nicolle LE, Harding GKM (1995) Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. Clin Infect Dis 21:316–322
Zheng X, Zhang G (2014) Imaging pulmonary infectious diseases in immunocompromised patients. Radiol Infect Dis 1:37–41. https://doi.org/10.1016/j.rid.2014.11.001
Zimlichman E et al (2013) Health care–associated infections: a meta-analysis of costs and financial impact on the US health care system. JAMA Intern Med 173:2039–2046

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.